Exome Sequencing Provides Diagnostic Assay for Intellectual Disability
|
By LabMedica International staff writers Posted on 22 Nov 2012 |
A molecular based diagnostic assay has been used determine whether one or more genetic mutations explain a patient's intellectual disability.
Exome sequencing, which deciphers over 21,000 protein-coding genes and not the entire human genome, can be used as a diagnostic assay to determine the genetic mutations that may elucidate why some patients suffer from significant limitations both in intellectual functioning and in adaptive behavior.
A team of scientists at Radboud University (Nijmegen, The Netherlands) performed exome sequencing of 100 patients with unexplained cognitive impairment, and uncovered 79 genes with unique de novo mutations. These de novo mutations were present in the DNA of the patients but not in that of their parents whose exomes also were sequenced.
The diagnostic interpretation revealed that 16 of the 100 mutations were causative, or pathogenic. Ten of these mutations occurred in genes already known to be involved in intellectual disability, and three X-linked maternally inherited mutations were identified. In addition, de novo mutations were uncovered in three novel candidate genes, which after follow-up were found to be more frequently mutated in patients with intellectual disability. Furthermore, disruptive de novo mutations were identified in 19 additional genes with a functional link to intellectual disability. Because 19 genes were found in only a single patient, a conclusive diagnosis based on these findings could not be made.
Joseph de Ligt, MSc, bioinformatician and PhD student in human genetics, said, “The child with a cognitive disability is often an isolated case without family history of the condition, and that intellectual disability occurs in about 1% of the population. All de novo as well as X-linked mutations identified in this study were interpreted in the context of the clinical diagnosis.” The results of this study were presented on November 8, 2012, at the American Society of Human Genetics meeting, held in San Francisco, (CA, USA).
Related Links:
Radboud University
Exome sequencing, which deciphers over 21,000 protein-coding genes and not the entire human genome, can be used as a diagnostic assay to determine the genetic mutations that may elucidate why some patients suffer from significant limitations both in intellectual functioning and in adaptive behavior.
A team of scientists at Radboud University (Nijmegen, The Netherlands) performed exome sequencing of 100 patients with unexplained cognitive impairment, and uncovered 79 genes with unique de novo mutations. These de novo mutations were present in the DNA of the patients but not in that of their parents whose exomes also were sequenced.
The diagnostic interpretation revealed that 16 of the 100 mutations were causative, or pathogenic. Ten of these mutations occurred in genes already known to be involved in intellectual disability, and three X-linked maternally inherited mutations were identified. In addition, de novo mutations were uncovered in three novel candidate genes, which after follow-up were found to be more frequently mutated in patients with intellectual disability. Furthermore, disruptive de novo mutations were identified in 19 additional genes with a functional link to intellectual disability. Because 19 genes were found in only a single patient, a conclusive diagnosis based on these findings could not be made.
Joseph de Ligt, MSc, bioinformatician and PhD student in human genetics, said, “The child with a cognitive disability is often an isolated case without family history of the condition, and that intellectual disability occurs in about 1% of the population. All de novo as well as X-linked mutations identified in this study were interpreted in the context of the clinical diagnosis.” The results of this study were presented on November 8, 2012, at the American Society of Human Genetics meeting, held in San Francisco, (CA, USA).
Related Links:
Radboud University
Latest Molecular Diagnostics News
- New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
- Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
- Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
- Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
- Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
- Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
- Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
- Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
- New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
- Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
- Liquid Biopsy Combines Multiple Signals for Cancer Detection in a Single Analysis
- Newborn Screening Program Adds Spinal Muscular Atrophy Testing Across England
- Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
- Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
- Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
- Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection
Channels
Clinical Chemistry
view channel
Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more
Blood Test Markers Could Help Identify Older Adults at Risk of Disability
Maintaining independence into very old age is a growing public health challenge as Japan’s population rapidly ages. Nearly 60% of Japanese adults aged 85 years and older already receive support through... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies
HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more







